Silychristin

Pharmacology & Research

Silychristin is a flavonolignan of the silymarin complex from milk thistle seed — a sibling of the dominant silybin (silibinin) and of isosilybin, at roughly 15–25% of the mixture. It has a genuine dual identity. First, it is typically the strongest direct radical scavenger of the common flavonolignans, out-scoring silybin in antioxidant assays ^{3Reference 3Sersen F et al. · 2006Silymarin and its components scavenge phenylglyoxylic ketyl radicalsView study →}. Second, and most distinctively, it is a potent, selective inhibitor of MCT8 (SLC16A2), the transporter that carries thyroid hormone across cell membranes ^{2Reference 2Johannes J et al. · 2016Silychristin, a flavonolignan derived from milk thistle, is a potent inhibitor of the thyroid-hormone transporter MCT8View study →} — which makes it a research tool and a theoretical thyroid-axis caution. As with the other congeners, milk thistle’s clinical evidence rests on the silymarin complex/silibinin, not isolated silychristin.

1. Antioxidant / radical scavenging

Silychristin’s signature. In head-to-head assays, DPPH scavenging ranked silymarin > silychristin > silydianin > silybin, and against phenylglyoxylic ketyl radicals silychristin was among the two most effective while silybin was ineffective ^{3Reference 3Sersen F et al. · 2006Silymarin and its components scavenge phenylglyoxylic ketyl radicalsView study →} — i.e. it is the strongest direct radical scavenger of the common flavonolignans, and a review names the non-silybin congeners as potentially superior antioxidants ^{1Reference 1Selc M · 2025Looking beyond silybin: the importance of other silymarin flavonolignansView study →}.

Gap: in-vitro chemistry only, with no cellular-outcome or human antioxidant-endpoint data for the isolate ^{3Reference 3Sersen F et al. · 2006Silymarin and its components scavenge phenylglyoxylic ketyl radicalsView study →}.

2. Hepatoprotective / cytoprotective

Silychristin contributes to the silymarin complex’s cyto-protection — for example against anthracycline toxicity in cardiomyocytes ^{5Reference 5Chlopčíková Š et al. · 2004AnimalChemoprotective effect of plant phenolics against anthracycline-induced toxicity on rat cardiomyocytes: silymarin and its flavonolignansView study →} and to the skin-protective (UV/oxidative) activity of the flavonolignan set ^{4Reference 4Vostálová J et al. · 2019Skin-protective activity of silymarin and its flavonolignansView study →}.

Gap: the actual hepatoprotective clinical evidence belongs to silymarin/silibinin, not isolated silychristin — do not transfer trial efficacy to this molecule ^{1Reference 1Selc M · 2025Looking beyond silybin: the importance of other silymarin flavonolignansView study →}.

3. MCT8 inhibition (research tool / caveat)

The best-characterised molecular action of isolated silychristin: it is a potent (IC50 ~100 nM) and unusually selective inhibitor of MCT8/SLC16A2, the thyroid-hormone transporter (specific for MCT8 versus MCT10), and is used as a pharmacological MCT8 probe ^{2Reference 2Johannes J et al. · 2016Silychristin, a flavonolignan derived from milk thistle, is a potent inhibitor of the thyroid-hormone transporter MCT8View study →}.

Gap: this is a caveat and a research tool, not an efficacy claim — and the original authors themselves raise questions about safety with respect to unwanted effects on the thyroid-hormone axis ^{2Reference 2Johannes J et al. · 2016Silychristin, a flavonolignan derived from milk thistle, is a potent inhibitor of the thyroid-hormone transporter MCT8View study →}.

Mechanisms

Target / pathway	Effect	Relevant to
Free radicals (DPPH, ketyl radicals)	direct scavenging, stronger than silybin in vitro	antioxidant (primary hook)
Nrf2 / antioxidant-response (class-level)	proposed induction of cytoprotective genes (inferred, not isolate-proven)	antioxidant, cytoprotective
MCT8 / SLC16A2 (thyroid-hormone transporter)	potent, selective inhibition (IC50 ~100 nM)	distinctive pharmacology + safety caveat

Pharmacokinetics

Silychristin shares the flavonolignan class’s poor aqueous solubility and poor oral bioavailability — the seed complex is not water-soluble, so teas do not deliver a meaningful dose, and standardised extracts or phospholipid complexes are used for the parent complex ^{1Reference 1Selc M · 2025Looking beyond silybin: the importance of other silymarin flavonolignansView study →}. There is no dedicated human pharmacokinetic study of the isolate, so low systemic exposure from oral intake should be assumed — and importantly, the ~100 nM in-vitro MCT8 potency is a cell-assay figure, not an achieved plasma concentration.

Clinical trials

There are no human trials of isolated silychristin. All human evidence associated with milk thistle is on the silymarin complex or silibinin/silybin (NAFLD, chronic liver disease, IV Legalon SIL for Amanita poisoning), not this single molecule — those outcomes must not be presented as silychristin efficacy.

Last checked: July 2026.

Toxicity & Safety

Silychristin has a [low] toxicity verdict for the flavonolignan itself — no signal of intrinsic toxicity, and it reaches humans normally only as a minor fraction of a well-tolerated seed extract. The distinctive concern that must be flagged is MCT8 inhibition: silychristin is a potent and unusually selective inhibitor of the transporter that carries thyroid hormone (T3/T4) across cell membranes, and loss-of-function MCT8 mutations cause a severe neurodevelopmental disorder ^{2Reference 2Johannes J et al. · 2016Silychristin, a flavonolignan derived from milk thistle, is a potent inhibitor of the thyroid-hormone transporter MCT8View study →}. In principle meaningful MCT8 inhibition could perturb tissue-level thyroid-hormone distribution — this remains theoretical for normal oral intake (bioavailability is poor and achieved concentrations are likely well below the in-vitro IC50), but it is a genuine, well-cited property, so the rating is [low] with an explicit thyroid-axis caveat rather than unqualified. Asteraceae-allergy caution applies to milk-thistle products generally.

Pregnancy & lactation

Precautionary — avoid the isolate. Thyroid-hormone transport (and MCT8 specifically) is critical to fetal neurodevelopment, and silychristin is a selective MCT8 inhibitor ^{2Reference 2Johannes J et al. · 2016Silychristin, a flavonolignan derived from milk thistle, is a potent inhibitor of the thyroid-hormone transporter MCT8View study →}; concentrated isolated silychristin is not studied in pregnancy, so the theoretical fetal-brain/thyroid concern warrants avoiding the purified isolate in pregnancy and lactation.

Dosage

There is no established therapeutic dose — silychristin is not sold or dosed as an isolate and is consumed only as ~15–25% of a standardised silymarin extract, so no dosing recommendation can be made and any figure would be extrapolation from the complex.

References

1. Selc M, Babelova A (2025). Looking beyond silybin: the importance of other silymarin flavonolignans. Frontiers in Pharmacology. https://pubmed.ncbi.nlm.nih.gov/40761399/
2. Johannes J, et al. (2016). Silychristin, a flavonolignan derived from milk thistle, is a potent inhibitor of the thyroid-hormone transporter MCT8. Endocrinology. https://pubmed.ncbi.nlm.nih.gov/26910310/
3. Sersen F, et al. (2006). Silymarin and its components scavenge phenylglyoxylic ketyl radicals. Fitoterapia. https://pubmed.ncbi.nlm.nih.gov/16956731/
4. Vostálová J, et al. (2019). Skin-protective activity of silymarin and its flavonolignans. Molecules. https://pubmed.ncbi.nlm.nih.gov/30875758/
5. Chlopčíková Š, et al. (2004). Chemoprotective effect of plant phenolics against anthracycline-induced toxicity on rat cardiomyocytes: silymarin and its flavonolignans. Phytotherapy Research. https://pubmed.ncbi.nlm.nih.gov/15022159/